| [1] |
Kozlow W, Guise TA.Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy[J].J Mammary Gland Biol Neoplasia, 2005, 10(2): 169-180. |
| [2] |
Mundy GR.Metastasis to bone: causes, consequences and therapeutic opportunities[J].Nat Rev Cancer, 2002, 2(8): 584-593. |
| [3] |
吕靖, 马彩玲.绝经后骨质疏松症的治疗新进展[J].医学综述, 2007, 13(1): 62-63. |
| [4] |
刘鹏熙, 周瑞芳, 许锐, 等.唑来膦酸与帕米膦酸二钠治疗乳腺癌骨转移性疼痛的近期疗效观察[J/OL].中华乳腺病杂志: 电子版, 2008, (4): 402-406[2014-01-13].http://cjbd.xnyy.cn/cn/index.asp. |
| [5] |
Finlay IG, Mason MD, Shelley M.Radioisotopes for the palliation of metastatic bone cancer: a systematic review[J].Lancet Oncol, 2005, 6(6): 392-400. |
| [6] |
潘中允.放射性核素治疗学[M].北京:人民卫生出版社, 2006: 217. |
| [7] |
翟士军, 万卫星, 吴娜静, 等.89SrCL2联合唑来膦酸治疗转移性骨肿瘤的疗效观察[J].中国辐射卫生, 2013, 22(4): 404-406. |
| [8] |
Body JJ.Clinical research update; zoledronate[J].Cancer, 1997, 80(8 Suppl): S1699-1701. |
| [9] |
Skerjance A, Berenson J, Hsu C, et al.The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function[J].J Clin Pharmacol, 2003, 43(2): 154-162. |
| [10] |
Neville-Webbe HI, Coleman RE.The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia[J].Palliat Med, 2003, 17(6): 539-553. |
| [11] |
Matsumoto S, Kimuta S, Seqawa H, et al.Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines[J].Lung Cancer, 2005, 47(1): 31-39. |
| [12] |
Croucher P, Jagdev S, Coleman R.The anti-tumor potential of zoledronic acid[J].Breast, 2003, 12 Suppl 2: S30-36. |